Molecular Markers of Chemotherapy Response in Colorectal Cancer

Biomarkers with predictive value and, to a lesser extent, prognostic value hold the potential to revolutionize the clinical practice of oncology. During the past 20 years, this has been an active field for basic and translational research in colorectal cancer, but no validated biomarkers have been i...

Full description

Saved in:
Bibliographic Details
Published inCurrent colorectal cancer reports Vol. 6; no. 3; pp. 118 - 125
Main Authors Braun, Michael S., Seymour, Matthew T.
Format Journal Article
LanguageEnglish
Published New York Current Science Inc 01.07.2010
Subjects
Colorectal Surgery
Medicine
Medicine & Public Health
Oncology
Proctology
Panitumumab
BRAF
EGFR
Prognostic
Bevacizumab
Irinotecan
Topoisomerase 1
Oxaliplatin
Mismatch repair
Predictive
Biomarkers
KRAS
Cetuximab
Fluorouracil
Online AccessGet full text

Cover

More Information
Summary:Biomarkers with predictive value and, to a lesser extent, prognostic value hold the potential to revolutionize the clinical practice of oncology. During the past 20 years, this has been an active field for basic and translational research in colorectal cancer, but no validated biomarkers have been identified or have become routine tools in clinical practice. The past decade has seen significant developments, with translational research projects being allied to randomized trials and the first fruit being borne with the identification of mismatch repair status, KRAS mutations, and possibly topoisomerase 1 expression as biomarkers with the potential to guide clinical practice.
ISSN:1556-3790
1556-3804
DOI:10.1007/s11888-010-0052-3